Key points are not available for this paper at this time.
Bruton tyrosine kinase (BTK) inhibitors have improved chronic lymphocytic leukemia (CLL) outcomes and offer a chemotherapyfree option The BTK inhibitor ibrutinib, alone or with a CD20 antibody, demonstrated better efficacy versus chemoimmunotherapy in treatment-nave (TN) CLL However, cardiovascular toxicity is a concern with continuous ibrutinib use
Sharman et al. (Sat,) studied this question.